Publications
Suresh A, Pan D, Lipof J, Kumar A, Arora S, Sayre P, Wolf J, Martin T, Chari A, Chung A. How should we choose optimal salvage treatments following BCMA-directed CAR T-cell therapy? Immunotherapy. 2025. PMID: 41104991
Suresh A, Pan D, Lipof J, Kumar A, Arora S, Sayre P, Wolf J, Martin T, Chari A, Chung A. How should we choose optimal salvage treatments following BCMA-directed CAR T-cell therapy? Immunotherapy. 2025. PMID: 41104991
Suresh A, Pan D, Lipof J, Kumar A, Arora S, Sayre P, Wolf J, Martin T, Chari A, Chung A. How should we choose optimal salvage treatments following BCMA-directed CAR T-cell therapy? Immunotherapy. 2025. PMID: 41104991
Suresh A, Pan D, Lipof J, Kumar A, Arora S, Sayre P, Wolf J, Martin T, Chari A, Chung A. How should we choose optimal salvage treatments following BCMA-directed CAR T-cell therapy? Immunotherapy. 2025. PMID: 41104991
Avigan ZM, Catlett J, Bodnar S, Pan D, Aleman A, Sheng T, Moshier E, Rossi AC, Richard S, Kaur G, Richter J, Sanchez LJ, Rodriguez C, Cho HJ, Hussein S, Salib C, Silverman LR, Jagannath S, Parekh S, Thibaud S. Clonal Hematopoiesis and Inflammation Predict Hematologic Toxicity and Secondary Myeloid Malignancies after B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2025. PMID: 40801897
Woodard GA, Kramer RJ, Blakely CM. Neoadjuvant Tyrosine Kinase Inhibitors. Thoracic surgery clinics. 2025. PMID: 41260725
Zhu L, Cheung YM, Chiang C, Gallagher EJ, Hamnvik OR, Mammen J, Quandt Z, Jones R, McDunn J, Al-Bahadili H, Angell T, Bancos I, Betof Warner A, Blackwell S, Calabrese C, Cho TA, Dougan M, Ferreira M, Funchain P, Herndon J, Johnson DB, Kennedy R, Kheterpal M, Khouri M, Lechner MG, Lim AM, Markova A, Meara A, Overton L, Perdigoto AL, Sachithanandan N, Sharon E, Spain L, Tsai K, Yarchoan M, Reynolds KL, Shariff A. Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitors. Journal for immunotherapy of cancer. 2025. PMID: 41093625
Chowdhury S, Gasper C, Lazar AA, Allaire K, Darragh TM, Fong L, Palefsky JM. Expression of Programmed Death-Ligand 1 and Programmed Cell Death-1 Across the Anal Neoplasia Disease Continuum and Association With Survival in Anal Cancer. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2025. PMID: 41106476
Finn RS, Rugo HS, Cortes J, Loibl S, Foley G, Gauthier E, Wang Y, Kim S, Anders L, Slamon DJ. A Decade After Approval of the First CDK4/6 Inhibitor: A Look Back at Palbociclib's Journey from Discovery to Approval and What's Next in CDK Inhibition in Breast Cancer. Targeted oncology. 2025. PMID: 41087648
Gelmon K, Villarreal-Garza C, Aubel D, S Rugo H, Maués J, Travado L, Van Meerveld M, C W Chidebe R, Patel B, Attfield G, Lewis A, Cardoso F. Improving the quality of life of people with advanced breast cancer: a global expert review and call-to-action for 2025-2035 (goal 3). Breast (Edinburgh, Scotland). 2025. PMID: 41298008
Ebadi M, Fan X, Schoch G, Gooley T, Rashidi A, Smith SD, Shadman M, Holmberg L, Ujjani C, Poh C, Raghunathan V, Ali N, Vo PT, Manjappa S, Menon M, Di M, Lynch R, Ho C, Till BG, Ermoian R, Gopal AK, Tseng YD. Total Body Irradiation Versus Chemotherapy-Only Conditioning in Autologous Haematopoietic Stem Cell Transplantation for Relapsed/Refractory Large B-cell Lymphoma. Clinical oncology (Royal College of Radiologists (Great Britain)). 2025. PMID: 41172559
Kiely B, Travado L, Smith AL, Timeus IA, Kim SB, Haidinger R, N M Nanre N, Rugo H, Attfield G, Lewis A, Cardoso F. Increasing awareness of and referral to support services in advanced breast cancer: a global expert review and call-to-action for 2025-2035 (Goal 7). Breast (Edinburgh, Scotland). 2025. PMID: 41298009
Jaishankar P, Correy GJ, Matsui Y, Togo T, Rachman MM, Stevens MGV, Hantz ER, Zheng J, Diolaiti ME, Montano M, Taha TY, Rosecrans J, Pampel J, Krogan NJ, Shoichet BK, Ashworth A, Ott M, Fraser JS, Renslo AR. Discovery of AVI-6451, a Potent and Selective Inhibitor of the SARS-CoV-2 ADP-Ribosylhydrolase Mac1 with Oral Efficacy in vivo. bioRxiv : the preprint server for biology. 2025. PMID: 41279160
Shah NJ, Shinde R, Bhattacharya R, LeMasters T, Ning N, Schmier J, Tan M, Vickery D, Perini R, Motzer RJ. Postimmunotherapy and Vascular Endothelial Growth Factor Inhibitor Landscape in Advanced Renal Cell Carcinoma: Treatment Patterns, Costs, and Outcomes. JCO oncology practice. 2025. PMID: 41082704
Oseran AS, Aggarwal R, Wadhera RK. Cardiovascular Risk Factor Management in Medicare Advantage and Traditional Medicare. Circulation. Cardiovascular quality and outcomes. 2025. PMID: 41064875
Bardossy ES, Bergmann L, Henrion-Lacritick A, Nigg J, Correy GJ, Ashworth A, Fraser JS, Saleh MC. Macrodomain ADP-ribose binding but not ADP-ribosylhydrolase activity is critical for chikungunya virus infection of Aedes mosquitoes. bioRxiv : the preprint server for biology. 2025. PMID: 41279946
Manabe T, Bergo HC, Li Q, Wang TS, Severson P, Miller N, Lee C, Donderici EY, Zhang N, Wu W, Chou YT, Kerr DL, Allegakoen P, Grandinetti KB, Soroceanu L, Pelham RJ, Martin ES, Murphy EA, Khanna V, Neal JW, Chen CT, Kato S, Williams R, Bivona TG. Targeting BRAF Class II and III Mutations in NSCLC with the pan-RAF inhibitor Exarafenib Reveals ARAF-KSR1-Mediated Resistance and Rational Combination Strategies. Research square. 2025. PMID: 41282105
Burstein HJ, Curigliano G, Gnant M, Loibl S, Regan MM, Loi S, Denkert C, Poortmans P, Cameron D, Thurlimann B, Weber WP, Panelists of the St. Gallen International Breast Cancer Consensus 2025. Electronic address: https://, Panelists of the St. Gallen International Breast Cancer Consensus 2025. Tailoring treatment to cancer risk and patient preference: the 2025 St Gallen International Breast Cancer Consensus Statement on individualizing therapy for patients with early breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2025. PMID: 41072918
Modi S, Jacot W, Iwata H, Park YH, Vidal Losada M, Li W, Tsurutani J, Ueno NT, Zaman K, Prat A, Papazisis K, Rugo HS, Yamashita T, Harbeck N, Im SA, De Laurentiis M, Pierga JY, Wang X, Gombos A, Tokunaga E, Orbegoso Aguilar C, Yung L, Xiao F, Cheng Y, Cameron D. Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial. Nature medicine. 2025. PMID: 41062831
Keenan BP, Qiao G, Kunda N, Kone L, Guldberg SM, Todeschini L, Kumar P, Pollini T, Hernandez S, Qin J, Fong L, Spitzer MH, Prabhakar BS, Maker AV. Combination LIGHT overexpression and checkpoint blockade disrupts the tumor immune environment impacting colorectal liver metastases. Science advances. 2025. PMID: 41061056